

## CURRICULUM VITAE

**Mingyi Chen MD, PhD**  
**Associate Professor of Pathology**  
**UT Southwestern Medical Center**  
**BioCenter; 2330 Inwood Rd. EB3.234A**  
**Dallas, Tx 75390**  
**Tel: 214-648-4791**  
**Email: [mingyi.chen@utsouthwestern.edu](mailto:mingyi.chen@utsouthwestern.edu)**

### **EDUCATION AND PROFESSIONAL EXPERIENCE:**

- 1986-1992 M.D., Peking University Health Science Center, (Beijing Medical University). China
- 1995-2001 Ph.D., Department of Pharmacology, Kyoto University and National Cardiovascular Center Research Institute, Japan
- 2001-2005 Postdoctoral Fellow, Howard Hughes Medical Institute/Dept. of Pathology and Laboratory Medicine, UCLA Medical Center
- 2005-2006 Pathology resident, Dept. of Pathology and Laboratory Medicine, UCSD, Medical Center
- 2006-2009 Pathology resident, Dept. of Pathology and Laboratory Medicine, Loma Linda University Medical Center
- 2009-2010 Hematopathology fellowship with Dr. Lawrence Weiss at City of Hope
- 2010-2014 Assistant professor of Pathology, Dept. of Pathology and Lab Medicine, University of California, Davis Medical Center
- 2014-2016 Associate professor of Pathology, Dept. of Pathology and Lab Medicine, University of California, Davis Medical Center
- 2014-2016 Associate medical director, Shriner hospital of northern California, Sacramento.
- 2016-present Associate professor of Pathology, Dept. of Pathology, UT Southwestern Medical Center
- 2016-present Medical director of hematology lab of Moncrief cancer institute of UTSW, Fort Worth.
- 2020 Professor of Pathology, Dept. of Pathology, UT Southwestern Medical Center

### **LICENSURE AND BOARD CERTIFICATION**

- Medical License of California and Texas
- Diplomate of the American Board of Pathology (Anatomic and clinical pathology) (08/2009)
- Diplomate of the American Board of Pathology in Hematology (10/2010)

### **CLINICAL INTERESTS**

- Hematopathology- lymphoma, leukemia flow cytometry, and diagnostic molecular pathology
- Pulmonary and GI tract hematolymphoid disease and bone marrow transplant

## Other Experience and Professional Memberships

- 2006- Member, United States and Canadian Academy of Pathology  
2010- Member, American Society of Hematology  
2012- Member, American Society of Clinical Oncology  
2013- Editor board of Clinical Journal of Microbiology and Pathology, Journal of Genomic Medicine, Journal of hematopathology, and Journal of Blood disorder  
2010- Expert Reviewer of Agency for Healthcare Research and Quality (AHRQ) Healthcare Horizon Scanning System, U.S. Department of Health & Human Services (HHS)

### Honors:

- American Heart Association Research Award Postdoctoral Fellowship (2002-2004)
- Geraldine C. Zeiler Pulmonary Pathology Fellowship at Mayo Clinic in Arizona (August, 2008)
- Travel award from ASCO “Markers in Cancer Diagnostic Development Tutorial: Developing Biomarkers from Discovery to Oncology Practice (September, 2012)
- International Society Hematology Presentation Award (September, 2014)

## RESEARCH INTERESTS

- Biomarker development of cancer diagnosis, cancer stem cells, immunotherapy.
- Molecular pathogenesis of lymphoma and leukemia, tumor immunology and GVHD
- Atherosclerosis, thrombosis, vascular biology, sickle cell disease and lipid metabolism

## SELECTED PEER REVIEWED PUBLICATIONS:

1. Zhang J, Sun W, Kong X, Zhang Y, Yang HJ, Ren C, Jiang Y, **Chen M**, Chen X. Mutant p53 Antagonizes p63/p73-Mediated Tumor Suppression via Notch1. *Proc Natl Acad Sci U S A*. 2019 Nov 26;116(48):24259-24267.
2. Shi M, Hu X, **Chen M**. Therapy induced acute myeloid leukemia in HIV positive patient with history of chemotherapy. *J Hematopathol* 2019 12(4), 213-214.
3. Hu X, **Chen M**. Coincidence of Therapy Related Acute Myeloid Leukemia and Metastatic Breast Cancer. Haematology images *British Society for Haematology* 2019
4. Gu Z, Liu Y, Cai F, Patrick M, Zmajkovic J, Cao H, Zhang Y, Tasdogan A, **Chen M**, Qi L, Liu X, Li K, Lyu J, Dickerson KE, Chen W, Ni M, Merritt ME, Morrison SJ, Skoda RC, DeBerardinis RJ, Xu J. Loss of EZH2 Reprograms BCAA Metabolism to Drive Leukemic Transformation. *Cancer Discov*. 2019 Sep;9(9):1228-1247.
5. Liu Z, Han C, Dong C, Shen A, Hsu E, Ren Z, Lu C, Liu L, Zhang A, Timmerman C, Pu Y, Wang Y, **Chen M**, Qiao J, Fu YX. Hypo-fractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunity. *Science Immunol*. 2019 Aug 9;4(38). pii: eaav6473.
6. Gong Z, Xu ML, **Chen M**, Cui W, Kantarjian HM, Cortes JE, Zhou T, Tang G, Wang W, Medeiros LJ, Hu S. Philadelphia chromosome-negative acute leukemia in chronic myeloid leukemia. *Am J Hematol*. 2019 Jul 4. doi: 10.1002/ajh.25571.
7. Zhang Y, Feng X, Zhang J, **Chen M**, Huang E, Chen X. Iron Regulatory Protein 2 Is a Suppressor of Mutant p53 in Tumorigenesis. *Oncogene* 2019 Jul 22. doi: 10.1038/s41388-019-0876-5.

8. Shi M, Xu F, Yang X, Bai Y, Niu J, Drokow EK, **Chen M**, Chen Y, Sun K. The synergistic antileukemic effects of Eltrombopag and Decitabine in myeloid leukemia cells. *Cancer Management and Research*. V11:8229-8238.
9. Yuan J, Li S, Liu X, Su RJ, **Chen M**, Wu X, Zheng G, Smith LM, Wang L, Li Y, Liu C, Zhou J, Shen Q, Zhang L, Wang E, Xu ML, Pan Z. Mantle Cell Lymphoma With Mantle Zone Growth Pattern. *Am J Clin Pathol*. 2019 May 29. pii: aqz043. doi: 10.1093/ajcp/aqz043.
10. Shi M, Jeanna Su R, Parmar KP, Chaudhry R, Sun K, Rao J, **Chen M**. CD123 a novel biomaker for diagnosis and treatment of leukemia. *Cardiovasc Hematol Disord Drug Targets*. 2019 Jun 26. doi: 10.2174/1871529X19666190627100613.
11. Pai CS, Huang JT, Lu X, Simons DM, Park C, Chang A, Tamaki W, Liu E, Roybal KT, Seagal J, **Chen M**, Hagihara K, Wei XX, DuPage M, Kwek SS, Oh DY, Daud A, Tsai KK, Wu C, Zhang L, Fasso M, Sachidanandam R, Jayaprakash A, Lin I, Casbon AJ, Kinsbury GA, Fong L. Clonal deletion of tumor-specific T cells by IFN- $\gamma$  confers therapeutic resistance to combination immune checkpoint blockade. *Immunity*. 2019 Feb 19;50(2):477-492.
12. Lucchesi CA, Zhang J, Ma B, **Chen M**, Chen X. Disruption of the Rbm38-eIF4E complex with a synthetic peptide Pep8 increases p53 expression. *Cancer Res*. 2019 Feb 15;79(4):807-818.
13. Pai CS, Simons DM, Lu X, Evans M, Wei J, Wang YH, **Chen M**, Huang J, Park C, Chang A, Wang J, Westmoreland S, Beam C, Banach D, Bowley D, Dong F, Seagal J, Ritacco W, Richardson PL, Mitra S, Lynch G, Bousquet P, Mankovich J, Kingsbury G, Fong . Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity. *J. Clin. Invest*. 2019 Jan 2;129(1):349-363.
14. Wang T, Lu R, Kapur P, Jaiswal BS, Hannan R, Zhang Z, Pedrosa I, Luke JJ, Zhang H, Goldstein LD, Yousuf Q, Gu YF, McKenzie T, Joyce A, Kim MS, Wang X, Luo D, Onabolu O, Stevens C, Xie Z, **Chen M**, Filatenkov A, Torrealba J, Luo X, Guo W, He J, Stawiski E, Modrusan Z, Durinck S, Seshagiri S, Brugarolas J. An Empirical Approach Leveraging Tumorgrafts to Dissect the Tumor Microenvironment in Renal Cell Carcinoma Identifies Missing Link to Prognostic Inflammatory Factors. June 2018, *Cancer Discov*. 2018 Sep;8(9):1142-1155.
15. Jiang YQ, Xu E, **Chen M**, Flores E. Zhang J, and Chen X. The Rbm38- p63 Feedback Loop Is Critical for Tumor Suppression and Longevity. *Oncogene*, 2018 Mar;223:207-214.
16. Henderson T, **Chen M**, Darrow, Li CS, Chiu CL, Monjazebe AM, Murphy WJ, Canter RJ. Alterations in cancer stem-cell marker CD44 expression predict oncologic outcome in soft-tissue sarcomas. *Journal of Surgical Research*, 2018 Mar;223:207-214.
17. Zhang J, Xu E, Ren C, Yang HJ, Zhang Y, Sun W, Kong X, **Chen M**, Huang E, and Chen X. Loss of Rbm38 Cooperates with Mutant p53 to Promote Lymphomagenesis through Downregulation of Pten. *Cancer research*. 2018 Mar 15;78(6):1511-1521.
18. Pan Z, **Chen M**, Zhang Q, Wang E, Yin L, Xu Y, Huang Q, Zhang X, Zheng G, and Yuan J. CD3-Positive Plasmablastic B-Cell Neoplasms: A Diagnostic Pitfall. *Modern Pathology*, 2018 May;31(5):718-731.
19. Liu Z, Liu H, Shi M, Ahmed HWA, Huo L, MD; Zhang Y, Wen M, **Chen M**, William J. Murphy JW, Sun K. Donor HSCs with preexisting ASXL1-mutation led to the development of FLT3-ITD positive AML in the donor and FLT3-ITD negative AML in the recipient after unrelated transplant. *Blood Marrow Transplant*. 2018 Apr;53(4):499-502.
20. RJ Su, R. Green, **Chen M**. Enumeration of bone marrow plasmacytoid dendritic cells by multiparameter flow cytometry as a prognostic marker following allogeneic hematopoietic stem cell transplantation. *Blood Cells Mol Dis*. 2018 Mar;69:107-112.
21. Tang H, Liang Y, Anders RA, Taube JM, Qiu X, Harrington SM, Guo J, Xin Y, Xiong Y, Nham K, Silvers W, Hao G, Sun X, **Chen M**, Hannan R, Qiao J, Peng H, Fu1, YX. PD-L1 on host cells is

- essential for tumor regression mediated by PD-L1 blockade. *J Clin Invest*. 2018 Feb 1;128(2):580-588.
22. Wick N., and **Chen M**. Central Nervous System Myelomatosis in the Era of Precision Medicine. *Hematopathol* 2018;1(2):108
  23. Shi M, Su R, Parmar K, Kai Sun, Rao JY, Chen M. CD123 a novel biomaker for diagnosis and treatment of leukemia. *Cardiovascular & Hematological Disorders - Drug Targets*. In press.
  24. Frame IJ, Coberly J, Fuda FS, **Chen M**. Erythrophagocytosis by T-cell lymphoma cells in a patient with hereditary spherocytosis post-splenectomy. *Br J Haematol*. 2018 Mar;180(6):781.
  25. Zhang Y, Qian Y, Zhang J, Yan W, Jung YS, **Chen M**, Huang E, Lloyd K, Duan Y, Wang J, Liu G, Chen X. Ferredoxin reductase is critical for p53-dependent tumor suppression via iron regulatory protein 2. *Genes Dev*. 2017 Jun 15;31(12):1243-1256.
  26. Yang HJ, Zhang J, Yan W, Cho SJ, Lucchesi C, **Chen M**, Huang EC, Scoumanne A, Zhang W, Chen X. Ninjurin 1 has two opposing functions in tumorigenesis in a p53-dependent manner. *Proc Natl Acad Sci U S A*. 2017 Oct 24;114(43):11500-11505. doi: 10.1073/pnas.1711814114.
  27. Qiu X, Tang H, **Chen M**. Detection of PDL-1 as of Biomarker in Checkpoint Blockade Therapy. *Clin Oncol*. 2017; 2: 1368.
  28. Canter RJ; Grossenbacher SK; Foltz JA; Sturgill IR; Park JS; Luna JI; Kent MS; Culp WT; **Chen M**; Modiano JF; Monjazebe AM; Lee DA; Murphy WJ. Radiotherapy Enhances Natural Killer Cell Cytotoxicity and Localization in Pre-Clinical Canine Sarcomas and First-in-Dog Clinical Trial. *J Immunother Cancer*. 2017 Dec 19;5(1):98. doi: 10.1186/s40425-017-0305-7.
  29. Pai CS, Khuat LT, **Chen M**, Murphy WJ, Abedi M. Therapeutic Effects of a NEDD8-Activating Enzyme Inhibitor, Pevonedistat, on Sclerodermatous Graft-versus-Host Disease in Mice. *Biol Blood Marrow Transplant*. 2017 Jan;23(1):30-37.
  30. Pan Z, Hu S, Li M, Zhou Y, Kim YS, Reddy V, Sanmann JN, **Chen M**, Gao Z, Wang HY, Yuan J. ALK-Positive Large B-Cell Lymphoma: A Clinicopathologic Study of 26 Cases with Review of Additional 108 Cases in the Literature. *Am J Surg Pathol*. 2017 Jan;41(1):25-38.
  31. Lei L, Raghavan R, **Chen M**, Wang J, Kerstetter J (2016) Primary Cutaneous Hodgkin Lymphoma: A Revisit and Case Report. *Int Clin Pathol J*. 3(1): 00067.
  32. Park JS; Withers SS; Modiano, JF; **Chen M**; Luna JL; Arta M. Monjazebe; Murphy WJ; Canter RJ. Canine Cancer Immunotherapy Studies: Linking Mouse and Human. *J Immunother Cancer*. 2016 Dec 20;4:97.
  33. **Chen M**, Qiu H, Lin X, Nam D, Ogbu-Nwobodo L, Archibald H, Josin A, Wun T, Sawamura T, and Green R. Expression of Lectin-like oxidized low-density lipoprotein receptor (LOX-1) in sickle cell disease vasculopathy. *Blood Cells, Molecules and Diseases*, 60(September 2016): 44–48.
  34. Su RJ, Jonas BA, Welborn J, Gregg JP, **Chen M**. Chronic eosinophilic leukemia, NOS with t(5;12)(q31;p13)/ETV6-ACSL6 gene fusion: a novel variant of myeloid proliferative neoplasm with eosinophilia. *Hum Pathol (N Y)*. 2016 Sep;5:6-9.
  35. Su RJ, Huang EC, and **Chen M**. Central nervous system relapsed B-Lymphoblastic Leukemia with t(9;22)(q34;q11) BCR/ABL1 mimicking acute myeloid leukemia. *Hematopathol* 2016;1(2):108-113
  36. Qiu H and **Chen M**. Leukocytes in Obesity and after Bariatric Surgery: comment on: the effect of different bariatric surgery type on the leukocyte formula. *Surg Obes Relat Dis*. 2016 Mar 7. pii: S1550-7289(16)00092-7.
  37. Monjazebe AM, Kent MS, Grossenbacher SK, Mall C, Zamora AE, Mirsoian A, **Chen M**, Kol A, Shiao SL, Reddy A, Perks JR, Culp W, Sparger EE, Canter RJ, Sckisel GD, and Murphy WJ. Blocking Indolamine-2,3-Dioxygenase Rebound Immune Suppression Boosts Anti-tumor Effects of Radio-Immunotherapy in Murine Models and Spontaneous Canine Malignancies. *Clinical Cancer Research*. 2016 Sep 1;22(17):4328-40.

38. Mall C, Sckisel G, Proia DA, Mirsoian A, Pai CCS, **Chen M**, Monjazez A, Kelly K, Blazar BR, and Murphy WJ. Repeat PD-1/PD-L1 monoclonal antibody administration induces fatal hypersensitivity reactions in a murine model of breast cancer. *OncoImmunology*. 2015 Aug 12;5(2):e1075114. eCollection 2016 Feb.
39. Matsukuma KE, Wei D, Sun K, Ramsamooj R, and **Chen M**. Diagnosis and differential diagnosis of hepatic Graft versus Host Disease (GVHD). *J Gastrointest Oncol* 2016;7(Suppl 1):S21-S31.
40. Sterling A., Jonas B. Rashidi H. Abedi M. and **Chen M**. Acute myeloid leukemia with extensive myelofibrosis and osteosclerosis in Cancer-Associated Fibroblasts. *Cancers* (Basel). 2015 Dec 14;7(4):2459-65.
41. Yokdang N, Hatakeyama J, Wald J, Simion C, Tellez J, Chang D, Swamynathan M, **Chen M**, Murphy WJ, and Sweeney C. LRIG1 opposes epithelial to mesenchymal transition and inhibits invasion of basal-like breast cancer cells. *Oncogene*. 2015 Sep 21. doi: 10.1038/onc.2015.345.
42. Robert Canter, Steven K Grossenbacher, Jiwon Sarah Park, Jaime Modiano, Erik Ames, Stephanie Mac, Arta M Monjazez, Michael Kent, William Culp, **Mingyi Chen** and William Murphy. Combination radioimmunotherapy with adoptive NK transfer targets cancer stem cells in canine models of bone and soft tissue sarcoma. *Journal for ImmunoTherapy of Cancer*, 2015(3(Suppl 2)): P4.
43. Ames E, Canter RJ, Grossenbacher SK, Smith RC, Monjazez AM, **Chen M** and. Murphy WJ. Enhanced Targeting of Stem-Like Solid Tumor Cells with Radiation and Natural Killer Cells. *Oncoimmunology*. 2015 Jun 5;4(9):e1036212. eCollection 2015 Sep.
44. Sckisel GD, Mirsoian A, Bouchlaka MN, Tietze JK, **Chen M**, Blazar BR, Murphy WJ. Late administration of murine CTLA-4 blockade prolongs CD8-mediated anti-tumor effects following stimulatory cancer immunotherapy. *Cancer Immunol Immunother*. 2015 Dec;64(12):1541-52.
45. Ames E, Canter RJ, Grossenbacher SK, Mac S, **Chen M**, Smith RC, Hagino T, Perez-Cunningham J, Sckisel GD, Urayama S, Monjazez AM, Fragoso RC, Sayers TJ, Murphy WJ. NK Cells Preferentially Target Tumor Cells with a Cancer Stem Cell Phenotype. *J Immunol*. 2015 Oct 15;195(8):4010-9.
46. Islam AD, Selmi C, Datta-Mitra A, Sonu R, **Chen M**, Gershwin ME, Raychaudhuri SP. The changing faces of IgG4-related disease: Clinical manifestations and pathogenesis. *Autoimmun Rev*. 2015 Jun 23. pii: S1568-9972(15)00134-2.
47. Zhang J, Xu E, Ren C, Yan W, Zhang M, **Chen M**, Cardiff RD, Imai DM, Wisner E, and Chen X. Mice Deficient in RBM38, a Target of the p53 Family, are Susceptible to Accelerated Aging and Spontaneous Tumors. *Proc Natl Acad Sci U S A*. 2014 Dec 30;111(52):18637-42.
48. Pai CC, **Chen M**, Mirsoian A, Grossenbacher SK, Tellez J, Ames E, Sun K, Blazar BR, Murphy WJ, Mehrdad A. Treatment of Chronic Graft versus Host Disease with Bortezomib. *Blood*. 2014 Sep 4;124(10):1677-88.
49. Tellez, J, Jaing C, Wang J, Green R, and **Chen M**. Detection of Epstein-Barr virus (EBV) in human lymphoma tissue by a novel microbial detection array. *Biomark Res*. 2014 Dec 5;2(1):24..
50. Durham BH and **Chen M**. Overview of Pathogenesis of Autologous Graft-Versus-Host Disease. *Clinical Microbiology and Pathology*. 2014, 2014, 1(2): 011.
51. Mirsoian A, Boucklaka MN, Sckisel GD, **Chen M**, Pai CS, Maverakis,E, Spencer RG. Fishbein KF, Siddiqui S, Monjazez AM, Martin B, Maudsley S, Longo DL, Blazar BR, Taub DD, and Murphy WJ. Adiposity as a Principal Component of Lethal Cytokine Storm Following Immunotherapy in Aged Mice. *J Exp Med*. 2014 Nov 17;211(12):2373-83.
52. Canter RJ, Ames E, Mac S, Grossenbacher SK, **Chen M**, Li CS, Borys D, Smith RC, Tellez J, Sayers TJ, Monjazez AM, Murphy WJ. Anti-Proliferative but not Anti-Angiogenic Tyrosine Kinase Inhibitors Enrich for Cancer Stem Cells in Soft Tissue Sarcoma. *BMC Cancer* 2014 Oct 10;14(1):756.

53. Alvarez M, Bouchlaka MN, Sckisel GD, Sungur CM, **Chen M**, Murphy WJ. Increased Antitumor Effects Using IL-2 with Anti-TGF- $\beta$  Reveals Competition between Mouse NK and CD8 T Cells. *J Immunol*. 2014 Aug 15;193(4):1709-16.
54. Pai CC, Hsiao HH, Sun K, **Chen M**, Hagino T, Tellez J, Mall C, Blazar BR, Monjazez A, Abedi M, Murphy WJ. Therapeutic benefit of bortezomib on acute GVHD is tissue specific and is associated with IL-6 levels. *Biol Blood Marrow Transplant*. 2014 Jul 23. pii: S1083-8791(14)00448-50.
55. Zhang H, Li Y, Lin TY, Xiao K, Haddad AS, Henderson PT, Jonas BA, **Chen M**, Xiao W, Liu R, Lam KS, Pan CX. Nanomicelle Formulation Modifies the Pharmacokinetic Profiles and Cardiac toxicity of Daunorubicin. *Nanomedicine* (Lond). 2014 Aug;9(12):1807-20.
56. Bouchlaka M Sckisel G, **Chen M**, Mirsoan A, Zamora A, Monjazez A, Longo D, Blazar BR, Taub DD, Murphy WJ. Aging Predisposes to Acute Pro-inflammatory Cytokine Storm-Induced Pathologies Following Systemic Immune Stimulation. *J Exp Med*. 2013 210 (11): 2223.
57. **Chen M**, Abedi M. Atypical lymphocytosis and cold agglutinin hemolytic anemia associated with monoclonal gammopathy in HIV-infected patient with marrow involvement by diffuse large B-cell lymphoma. *Blood* 2013 November 28, 122 (23): 3711.
58. **Chen M**, Krishnamurthy A, Mohamed RA, Green R. Hematological disorders following gastric bypass surgery: emerging concepts of the interplay between nutritional deficiency and inflammation. *BioMed Research International*, 2013(205467): 1-8.
59. Sungur CM, Tang-Feldman YJ, Ames E, Alvarez M, **Chen M**, Longo DL, Pomeroy C, Murphy WJ. Murine natural killer cell licensing and regulation by T regulatory cells in viral responses. *Proc Natl Acad Sci U S A*. 2013 Apr 30; 110(18):7401-6.
60. Sonu R, **Chen M**. Primary lymphoproliferative disorders of the liver: a review and pragmatic guide to diagnosis. ASCP HEMATOPATHOLOGY NO 1. HP 14-1 (H-364), 49(1): 2167-2245.
61. Khojeini EV, Durham BH, and **Chen M**. Mantle Cell Lymphoma and Involvement of the Orbit and Ocular Adnexa. Case Reports in Pathology. 2013 581856-62.
62. **Chen M**, Olson K. Colonic graft-versus-host disease (GVHD) manifesting as eosinophilic colitis following autologous hematopoietic stem cell transplantation. *Blood*. 2013 May 16;121(20):4020.
63. **Chen M**, Green R. Circulating plasma cells with Russell bodies in osteosclerotic myeloma. *Blood* 2013 122:160.
64. **Chen M**, Van Ness M, Guo Y, Gregg J. Molecular pathology of pancreatic neuroendocrine tumors. *J Gastrointest Oncol*. 2012 Sep;3(3):182-8.
65. Van Ness M, Gregg J, Wang J, **Chen M**. Genetics and molecular pathology of gastric malignancy: Development of targeted therapies in the era of personalized medicine. *J Gastrointest Oncol*. 2012 Sep;3(3):243-51.
66. Khojeini EV, and **Chen M**. Primary amyloidosis pragmatic guide to diagnosis. LABQ series. ASCP 2014.
67. Sun K, Hsiao HH, Li M, Ames E, Bouchlaka M, Welniak LA, Hagino T, Jagdeo J, Pai CC, **Chen M**, Blazar BR, Abedi M, Murphy WJ. INF-gamma receptor-deficient donor t cells mediate protection from graft-versus-host disease and preserve graft-versus-tumor responses after allogeneic bone marrow transplantation. *J Immunol*. 2012 Aug 15;189(4):2033-42.
68. Bautista-Quach MA, Ake CD, **Chen M**, Wang J. Gastrointestinal lymphomas: Morphology, immunophenotype and molecular features. *J Gastrointest Oncol*. 2012 Sep;3(3):209-25.
69. Afify A, Das S, **Chen M**. Two Smalls in One: co-incident small cell carcinoma and small lymphocytic lymphoma in a lymph node diagnosed by fine-needle aspiration biopsy. *CytoJournal* 2012, 9(5):1-5.
70. Sonu R, Song J, **Chen M**. Extramedullary hematopoiesis associated with myeloproliferative neoplasm manifesting as pleural effusion: Case report and review of literature. *J Hematopathol* (24 May 2012), pp. 1-7.

71. Yang Y, Batth SS, **Chen M**, Borys D, Phan H. Enteropathy-associated T cell lymphoma presenting with acute abdominal syndrome: a case report and review of literature. *J Gastrointest Surg*. 2012 Jul;16(7):1446-9.
72. Sun K, Alvarez M, Ames E, Barao I, **Chen M**, Longo DL, Redelman D, Murphy WJ. Mouse NK Cell-Mediated Rejection of Bone Marrow Allografts Exhibits Patterns Consistent with Ly49 Subset Licensing. *Blood*. 2012 Feb 9;119(6):1590-8.
73. Sonu R, Gregg J, and **Chen M**. Splenic Marginal Zone Lymphoma with Isolated t(8;14)(q24.1;q32)/MYC Rearrangement. *J Hematopathol* (2012) 5 (3) 141-147.
74. **Chen M**, Argawal R., Nasser-Nik N, Sloman A, Weiss LM. Indeterminate cell tumor of spleen. *Human Pathology* 2012 Feb;43(2):307-11.
75. **Chen M**. Neoplasms of dendritic cells: related cell origins and diagnostic markers: fibroblastic reticulum cells and fibroblastic reticulum cell tumors show several immunophenotypic profiles-Reply. *Human Pathology*. (2012) Sep;43(9):1531-2.
76. **Chen M**, Kim Y, Huang Q, Chang K, Gaal K, Weiss LM. Acute myeloid leukemia with an unusual histologic pattern mimicking metastatic neoplasm in bone marrow: a diagnostic pitfall. *J Hematopathol* (2011) 4 (2):117–122.
77. **Chen M**, Wang J. Gaucher disease: review of the literature. *Arch Pathol Lab Med*. 2008 May;132(5):851-3.
78. Bradley MN, Hong C, **Chen M**, Joseph SB, Wilpitz DC, Wang X, Lusic AJ, Collins A, Hseuh WA, Collins JL, Tangirala RK, Tontonoz P. Ligand activation of LXR beta reverses atherosclerosis and cellular cholesterol overload in mice lacking LXR alpha and apoE. *J Clin Invest*. 2007 Aug;117(8):2337-46.
79. **Chen M**, Bradley MN, Beaven SW, Tontonoz P. Phosphorylation of the liver X receptors. *FEBS Lett*. 2006 Sep 4;580(20):4835-41.
80. Wolf P, **Chen M**. Tribute to Dr. Donald Moss's contribution to clinical pathology and clinical enzymology. *Acta Clinica Chimica*. 2006 369 106-107.
81. **Chen M**, Beaven S, Tontonoz P. Identification and characterization of two alternatively spliced transcript variants of human liver X receptor alpha. *J Lipid Res*. 2005 Dec;46(12):2570-9.
82. Arai S, Shelton JM, **Chen M**, Bradley MN, Castrillo A, Bookout AL, Mak PA, Edwards PA, Mangelsdorf DJ, Tontonoz P, Miyazaki T. A role for the apoptosis inhibitory factor AIM/Spalpha/Api6 in atherosclerosis development. *Cell Metab*. 2005 Mar;1(3):201-13.
83. **Chen M**, Sawamura T. Essential role of cytoplasmic sequences for cell-surface sorting of the lectin-like oxidized LDL receptor-1 (LOX-1). *J Mol Cell Cardiol*. 2005 Sep;39(3):553-61.
84. Pei L, Castrillo A, **Chen M**, Hoffmann A, Tontonoz P. Induction of NR4A orphan nuclear receptor expression in macrophages in response to inflammatory stimuli. *J Biol Chem*. 2005 Aug 12;280(32):29256-62.
85. Laffitte BA, Joseph SB, **Chen M**, Castrillo A, Repa J, Wilpitz D, Mangelsdorf D, Tontonoz P. The phospholipid transfer protein gene is a liver X receptor target expressed by macrophages in atherosclerotic lesions. *Mol Cell Biol*. 2003 Mar;23(6):2182-91.
86. Joseph SB, McKilligin E, Pei L, Watson MA, Collins AR, Laffitte BA, **Chen M**, Noh G, Goodman J, Hagger GN, Tran J, Tippin TK, Wang X, Lusic AJ, Hsueh WA, Law RE, Collins JL, Willson TM, Tontonoz P. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. *Proc Natl Acad Sci U S A*. 2002 May 28;99(11):7604-9.
87. Nakagawa T, Yasuda T, Hoshikawa H, Shimizu M, Kakinuma T, **Chen M**, Masaki T, Nakamura T, Sawamura T. LOX-1 expressed in cultured rat chondrocytes mediates oxidized LDL-induced cell death-possible role of dephosphorylation of Akt. *Biochem Biophys Res Commun*. 2002 Nov 22;299(1):91-7.

88. Nakagawa T, Akagi M, Hoshikawa H, **Chen M**, Yasuda T, Mukai S, Ohsawa K, Masaki T, Nakamura T, Sawamura T. Lectin-like oxidized low-density lipoprotein receptor 1 mediates leukocyte infiltration and articular cartilage destruction in rat zymosan-induced arthritis. *Arthritis Rheum.* 2002 Sep;46(9):2486-94.
89. **Chen M**, Masaki T, Sawamura T. LOX-1, the receptor for oxidized low-density lipoprotein identified from endothelial cells: implications in endothelial dysfunction and atherosclerosis. *Pharmacol Ther.* 2002 Jul;95(1):89-100.
90. **Chen M**, Nagase M, Fujita T, Narumiya S, Masaki T, Sawamura T. Diabetes enhances lectin-like oxidized LDL receptor-1 (LOX-1) expression in the vascular endothelium: possible role of LOX-1 ligand and AGE. *Biochem Biophys Res Commun.* 2001 Oct 5;287(4):962-8.
91. **Chen M**, Inoue K, Narumiya S, Masaki T, Sawamura T. Requirements of basic amino acid residues within the lectin-like domain of LOX-1 for the binding of oxidized low-density lipoprotein. *FEBS Lett.* 2001 Jun 22;499(3):215-9.
92. **Chen M**, Narumiya S, Masaki T, Sawamura T. Conserved C-terminal residues within the lectin-like domain of LOX-1 are essential for oxidized low-density-lipoprotein binding. *Biochem J.* 2001 Apr 15;355(Pt 2):289-96.
93. **Chen M**, Kakutani M, Naruko T, Ueda M, Narumiya S, Masaki T, Sawamura T. Activation-dependent surface expression of LOX-1 in human platelets. *Biochem Biophys Res Commun.* 2001 Mar 23;282(1):153-8.
94. **Chen M**, Kakutani M, Minami M, Kataoka H, Kume N, Narumiya S, Kita T, Masaki T, Sawamura T. Increased expression of lectin-like oxidized low density lipoprotein receptor-1 in initial atherosclerotic lesions of Watanabe heritable hyperlipidemic rabbits. *Arterioscler Thromb Vasc Biol.* 2000 Apr;20(4):1107-15.
95. Chen M, Sawamura T. Northern blot analysis to quantify gene expression in vascular diseases. *Methods Mol Med.* 1999;30:181-8.
96. Aoyama T, **Chen M**, Fujiwara H, Masaki T, Sawamura T. LOX-1 mediates lysophosphatidylcholine-induced oxidized LDL uptake in smooth muscle cells. *FEBS Lett.* 2000 Feb 11;467(2-3):217-20.

## SELECTED BOOK CHAPTER PUBLICATIONS

- 2019 Alsuwaidanand A, Fuda F, Chen W, and **Chen MY**: Enumeration of Bone Marrow Plasmacytoid Dendritic Cells by Flow Cytometry". J. Philip McCoy Jr.(ed), *Immunophenotyping: Methods and Protocols*, Methods Mol Biol. 2019;2032:193-201. doi: 10.1007/978-1-4939-9650-6\_11 Springer, New York.
- 2018 Su JR and **Chen MY**: Gamma-delta T-cell lymphoma, Krause J, Filicko-O'Hara J and Gulati G, (ed), *Case Studies in Hematology and Coagulation*, ASCP Press, Chicago, IL.
- 2016 Qiu H, Green R, **Chen MY**: Hematological disorders following bariatric surgery. Victor Preedy, (ed), *Pathophysiology of Bariatric Surgery: Metabolism, Nutrition, Procedures, Outcomes and Adverse Effects.*, Academic Press.
- 2013 Chen MY, Semrad T, Wang J.: *Diagnosis of Primary Gastrointestinal Lymphomas and Mimics*, Oncology Series, iConcept Press. 1998 Sawamura T., Chen MY, and Masaki T: LOX-1, an Endothelial Receptor for Oxidized LDL, Kita, T., (ed), *Lipoprotein Metabolism and Atherogenesis*, Springer Press.
- 2012 Chen MY and Chang K: T-cell prolymphocytic leukemia (T-PLL), Krause J, Filicko-O'Hara J and Gulati G, (ed), *Case Studies in Hematology and Coagulation*, ASCP Press, Chicago, IL.



- 2010 Chen MY: Molecular Biology of Glycogen Storage Diseases, P.S. Monga. eds. Philip T. Cagle, editor., (ed), Molecular Pathology of Liver Diseases, MOLECULAR PATHOLOGY, Vol. chapter 45, Springer's ISBN 978-1-4419-7106-7, pp. 677-682.
- 2001 Chen MY, Sawamura, T.: LOX-1, a Potential Inflammatory Mediators in Atherosclerosis, Mehta, JL, (ed), Inflammatory and Infectious Basis of Atherosclerosis, Birkhäuser Verlag press AG, Switzerland.
- 1999 Chen MY, Sawamura, T.: Northern Blot Analysis to Quantify Gene Expression in Vascular Disease, Baker, A.H., (ed), Method in Molecular Medicine, Humana Press Inc, NJ, USA.

### **Ongoing Research Support:**

- 01/01/2019-12/31/2023 RP180343 MIRA \$ 618,5684; Targeting Tumor Tissues Increases DNA Sensing to Bridge Innate and Adaptive Immunity. X. Fu (PI), UTSW pathology, CPRIT, Role: Co-Investigator/director of pathology core, 5% effort.
- 12/01/17-11//30/2022 Research Grant # 1R01 RCA224433A \$1350,000 X. Chen (PI)  
The goal of the study is to investigate the feedback loop between ferredoxin reductase and the p53 family in tumor suppression. The study will focus on ferredoxin reductase which plays a critical for p53-dependent tumor suppression via iron regulatory protein 2 signal transduction pathways. Role: Co-Investigator. 5% efforts
- 12/01/17-11//30/2020 RP180504 IIRA \$ 90,000; co-Investigator, Elucidating the Epigenetic and Metabolic Vulnerabilities of Myeloproliferative Neoplasms Award Mechanism: J. Xu (PI), UTSW Children's Medical Center Research Institute, CPRIT, Role: Collaborator, 3.3% efforts.
- 07/01/15-06/30/2019 Research Grant # 1R01CA192221-01A1 \$100,5684; co-Investigator, Nanoprobe-enabled Delineation of Tumor Margins for Improved Surgical Therapy: J. Gao (PI), UTSW Cancer Center, Role: Co-Investigator, 5% effort.
- 03/01/19-02/28/2020 RP180343 IIRA \$ 88,5684; co-Investigator, Turn ON the Tumor Contrast in Lymph Node Metastases for Occult Disease Detection: J. Gao (PI), UTSW Cancer Center, CPRIT, Role: Collaborator, 3% effort.
- 2/1/2019-1/31/2024 1R01CA230631-01A1, \$1100,000 NIH-NCI, Targeting Metabolic Liabilities of Leukemia-Initiating Cells. The overall objective of this project is to elucidate the mechanisms controlling branched-chain amino acid (BCAA) metabolism in leukemia stem cells. J. Xu (PI), Role: Collaborator, 3.3% effort.
- 01/01/2015-12/31/2018 Research Grant #1R01GM110050-01A1, \$1200,000, subcontract as co-Investigator, Highly Reactive Hydrazone Chemistry: Orthogonal Modification in Cellular Contexts, PI, Eric Kool PhD (PI) , Stanford University Department of Chemistry, NIH. Role: 5% efforts